Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 1.00 |
| ▸ | GSK3B | P49841 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11619693 | 0.84 | GSK3B (0.72) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL2337291 | 0.80 | GSK3A (0.67) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL23257946 | 0.80 | GSK3A (0.64) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL11711805 | 0.78 | GSK3A (0.64) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL3022499 | 0.75 | GSK3A (0.60) | GSK3AGSK3BGAAMEN1KMT2A | |
| SCHEMBL5328006 | 0.75 | GSK3A (0.60) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL3021600 | 0.75 | GSK3A (0.60) | GSK3AGSK3BGAAKMT2AL3MBTL1 | |
| SCHEMBL11876869 | 0.75 | GAA (0.60) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL5198556 | 0.75 | NTRK1 (0.72) | GSK3AGSK3BGAAMAPK1MEN1 | |
| SCHEMBL11363821 | 0.75 | GSK3A (0.60) | GSK3AGSK3BGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1028 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140108-A1 | EXTRACTION ROD AND PREPARATION METHOD THEREOF, AND METHOD FOR DETECTING 25-HYDROXYVITAMIN D | INNOVATION CENTER OF YANGTZE RIVER DELTA ZJU (CN) | 2026-05-21 | — | — | US | claimed |
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2026-04-21 | — | — | US | claimed |
| EP-4256347-B1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2025-07-16 | — | — | EP | claimed |
| US-20250216404-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-07-03 | — | — | US | claimed |
| US-12282032-B2 | Vitamin D metabolite determination utilizing mass spectrometry following derivatization | QUEST DIAGNOSTICS INVESTMENTS LLC (US) | 2025-04-22 | — | — | US | claimed |
| US-20240361344-A1 | METHODS FOR DETECTING DIHYDROXYVITAMIN D METABOLITES BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-10-31 | — | — | US | claimed |
| EP-3524958-B1 | METHODS FOR DETECTING DIHYDROXYVITAMIN D METABOLITES BY MASS SPECTROMETRY | QUEST DIAGNOSTICS INVEST INC (US) | 2024-09-25 | — | — | EP | claimed |
| US-12066446-B2 | Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2024-08-20 | — | — | US | claimed |
| CN-118090878-A | Method for detecting fat-soluble vitamins in biological sample | 中国科学技术大学 | 2024-05-28 | — | — | CN | claimed |
| US-20240103022-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-03-28 | — | — | US | claimed |
| US-4539153-A | Method of preparing 1 α-hydroxyvitamin D and 1 α-hydroxyprevitamin D compounds, and adducts of a previtamin D or tachysterol compound with a suitable dienophile | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1985-09-03 | — | — | US | claimed |
| EP-0070588-A1 | Method of preparing 1-alpha-hydroxyvitamin D and 1-alpha-hydroxy-previtamin D compounds, and adduct of a previtamin D or tachysterol compound with a suitable dienophile | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1983-01-26 | — | — | EP | claimed |
| US-4217288-A | Anti-vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1980-08-12 | — | — | US | claimed |
| US-4170707-A | Method for preparing 3,8-dicarbomethoxy-2,3,7,8-tetraazaspiro[4.4]nona-1,6-diene | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1979-10-09 | — | — | US | claimed |
| US-4170706-A | Method for preparing the bispicrate salt of 2,3,7,8-tetraazaspiro[4.4]nonane | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1979-10-09 | — | — | US | claimed |
| US-4125728-A | Method for preparing 2,3,7,8-tetraazaspiro[4,4]nona-2,7-diene | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1978-11-14 | — | — | US | claimed |
| US-4105660-A | Preparation of 3β-hydroxy-27-norcholest-5,7-dien-25-one | MERCK & CO., INC. (US) | 1978-08-08 | — | — | US | claimed |
| US-4088645-A | O,O-Dialkylphosphoryloxy-2,3,5,8-tetrahydro-1H-s-triazolo[1,2a]pyridazine-1,3-diones | HOFFMANN-LA ROCHE INC. (US) | 1978-05-09 | — | — | US | claimed |
| US-4066833-A | 2,3,7,8-Tetraazaspiro [4.4]nonane, 2,3,7,8-tetraazaspiro-[4.4]nona-2,7-diene and derivatives | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1978-01-03 | — | — | US | claimed |
| US-3979320-A | Liquid crystal composition | HODOGAYA CHEMICAL CO., LTD. (JA) | 1976-09-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | CYP24A1, CYP2R1, SRD5A1 | GSK3A 719/4885GSK3B 788/4885GAA 4777/4885 |
| US-20260140108-A1 | EXTRACTION ROD AND PREPARATION METHOD THEREOF, AND METHOD FOR DETECTING 25-HYDROXYVITAMIN D | VDR, CYP24A1, GC | GSK3A 444/4885GSK3B 421/4885GAA 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.